X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs SANOFI INDIA - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD SANOFI INDIA MERCK LTD/
SANOFI INDIA
 
P/E (TTM) x 50.9 39.9 127.7% View Chart
P/BV x 7.7 8.6 89.4% View Chart
Dividend Yield % 0.4 1.0 35.1%  

Financials

 MERCK LTD   SANOFI INDIA
EQUITY SHARE DATA
    MERCK LTD
Dec-16
SANOFI INDIA
Dec-16
MERCK LTD/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,0604,560 23.2%   
Low Rs6234,400 14.2%   
Sales per share (Unadj.) Rs632.41,028.5 61.5%  
Earnings per share (Unadj.) Rs45.7129.0 35.4%  
Cash flow per share (Unadj.) Rs62.3186.0 33.5%  
Dividends per share (Unadj.) Rs11.0068.00 16.2%  
Dividend yield (eoy) %1.31.5 86.1%  
Book value per share (Unadj.) Rs388.8753.6 51.6%  
Shares outstanding (eoy) m16.6023.03 72.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.4 30.5%   
Avg P/E ratio x18.434.7 53.0%  
P/CF ratio (eoy) x13.524.1 56.1%  
Price / Book Value ratio x2.25.9 36.4%  
Dividend payout %24.152.7 45.6%   
Avg Mkt Cap Rs m13,969103,174 13.5%   
No. of employees `0001.63.6 43.7%   
Total wages/salary Rs m1,4873,592 41.4%   
Avg. sales/employee Rs Th6,631.96,537.7 101.4%   
Avg. wages/employee Rs Th939.2991.4 94.7%   
Avg. net profit/employee Rs Th479.4819.8 58.5%   
INCOME DATA
Net Sales Rs m10,49823,686 44.3%  
Other income Rs m242708 34.2%   
Total revenues Rs m10,74124,394 44.0%   
Gross profit Rs m1,1355,281 21.5%  
Depreciation Rs m2761,313 21.0%   
Interest Rs m015 0.0%   
Profit before tax Rs m1,1024,661 23.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3431,691 20.3%   
Profit after tax Rs m7592,970 25.6%  
Gross profit margin %10.822.3 48.5%  
Effective tax rate %31.136.3 85.9%   
Net profit margin %7.212.5 57.7%  
BALANCE SHEET DATA
Current assets Rs m6,41015,673 40.9%   
Current liabilities Rs m8,8286,678 132.2%   
Net working cap to sales %-23.038.0 -60.7%  
Current ratio x0.72.3 30.9%  
Inventory Days Days5876 75.9%  
Debtors Days Days3822 172.0%  
Net fixed assets Rs m1,4068,098 17.4%   
Share capital Rs m166230 72.1%   
"Free" reserves Rs m6,28617,088 36.8%   
Net worth Rs m6,45517,356 37.2%   
Long term debt Rs m00-   
Total assets Rs m8,82825,400 34.8%  
Interest coverage xNM311.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.9 127.5%   
Return on assets %8.611.8 73.1%  
Return on equity %11.817.1 68.7%  
Return on capital %17.126.9 63.4%  
Exports to sales %8.324.5 33.8%   
Imports to sales %21.028.0 75.2%   
Exports (fob) Rs m8695,801 15.0%   
Imports (cif) Rs m2,2096,627 33.3%   
Fx inflow Rs m9597,145 13.4%   
Fx outflow Rs m2,6126,846 38.2%   
Net fx Rs m-1,653299 -552.9%   
CASH FLOW
From Operations Rs m1,0703,226 33.2%  
From Investments Rs m-750-1,555 48.2%  
From Financial Activity Rs m-150-1,818 8.2%  
Net Cashflow Rs m171-147 -116.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 60.4 85.8%  
Indian inst/Mut Fund % 18.2 14.4 126.4%  
FIIs % 1.0 14.6 6.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 10.5 277.1%  
Shareholders   28,591 15,184 188.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   FDC LTD.  UNICHEM LAB  WYETH LTD  AJANTA PHARMA  ALEMBIC LTD  

Compare MERCK LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE MERCK LTD WITH

MARKET STATS